LG AI Research and D&D Pharmatech have formalized a strategic partnership aimed at advancing the development of next-generation oral peptide drugs. This collaboration was announced following a signing ceremony at the LG Twin Towers in Yeouido, Seoul, marking a significant milestone in the pharmaceutical landscape.
The agreement underscores the growing interest in oral peptide formulations, which have traditionally faced challenges due to stability and bioavailability issues. By leveraging LG’s expertise in artificial intelligence and D&D Pharmatech’s innovative drug development capabilities, the partnership aims to overcome these hurdles and enhance patient compliance through more accessible oral delivery methods.
This collaboration not only highlights the importance of technological integration in drug development but also signals a shift in the industry towards more patient-friendly therapeutic options. As the demand for oral peptide drugs increases, this partnership could position both companies at the forefront of a rapidly evolving market.
Use the database as your supply chain compass →
